117th Congress · SENATE BILLBILL

S. 1428Preserve Access to Affordable Generics and Biosimilars Act

A bill to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products.

Health
Introduced Apr 28, 2021
Last action Dec 9, 2021
Pipeline · Bill → Law
Step 1
Introduced
Apr 28, 2021
Step 2
Referred
Apr 28, 2021
the Judiciary
Step 3
Committee
Jul 29, 2021
Reported out
Step 4
Senate
Dec 9, 2021
Step 5
House floor
Step 6
Resolve Changes
Step 7
Signed
SummaryNo summary available

No CRS summary available for this bill.

Provisions · 8 sectionsReported to Senate
Timeline · 5 actions
Dec 9, 2021
Committee on the Judiciary. Reported by Senator Durbin with an amendment in the nature of a substitute. Without written report.
Dec 9, 2021
Placed on Senate Legislative Calendar under General Orders. Calendar No. 180.
Jul 29, 2021
Committee on the Judiciary. Ordered to be reported with an amendment in the nature of a substitute favorably.
Apr 28, 2021
Introduced in Senate
Apr 28, 2021
Read twice and referred to the Committee on the Judiciary.